Monday, December 14, 2015

News: MiMedx Awarded 12 New U.S. Patents YTD 2015 With Four Awarded For Its Amniotic Membrane Allografts And Eight Awarded For Its CollaFix™ Technology

MARIETTA, Ga.Nov. 19, 2015 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced an update to its intellectual property portfolio.
Image result for MiMedx
Year-to-date in 2015, the U.S. Patent and Trademark Office has issued 12 new patents to MiMedx with four new patents issued for the Company's amniotic membrane allograft product lines and eight for the Company's CollaFix technology platform. Three of the 12 patents were issued to MiMedx since November 1, 2015. Two of these most recent patent issuances were related to the Company's amniotic membrane tissue allografts and one was related to the CollaFix technology. Since January 1, 2015, the U.S Patent Office has issued to MiMedx the following patents:

U.S. Patent Number
Patent Grant Date
"Placental tissue grafts"
"Cross-linked collagen comprising an antifungal agent"
"Cross-linked collagen comprising metallic anticancer agents"
"Implantable collagen devices and related methods and systems of making same"
"Compressible tubes for placing implants and related medical kits and methods of using same"
"Methods of making collagen fiber medical constructs and related medical constructs, including nerve guides and patches"
"Placental tissue grafts and methods of preparing and using the same"
"Biocomposite medical constructs including artificial tissues, vessels and patches"
"Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent"
"Compositions and methods for recruiting and localizing stem cells"
"Methods of making collagen fiber medical constructs and related medical constructs, including tubes"
"Placental tissue grafts produced by chemical dehydration/freeze-drying and methods for making and using the same"

Parker H. "Pete" Petit, Chairman and CEO, said, "We place a very high importance on developing and protecting the intellectual property of our Company. We are continually creating new intellectual property that augments our robust portfolio of patents. As of today, MiMedx has 27 issued patents and more than 100 patents pending for our amniotic tissue allografts, and 36 issued patents and over 35 patents pending for our CollaFix technology." 
Bill Taylor, President and COO, added, "We have stated in the past that we will continue to be extremely diligent in filing further patent applications related to our designs, methods and processes for both our amniotic membrane technology as well as our CollaFix technology. With our current status of more than 135 pending patent applications with the U.S Patent and Trademark Office, it should be evident that we have maintained a prolific pace of filing for new patent applications."
"Our aggressive approach to new patent filings and applications and our determined stand on enforcing our rights when our patents are infringed upon are the essential elements of protecting our intellectual property for our Company and our shareholders," noted Petit.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  Our biomaterial platform technologies are AmnioFix®, EpiFix®, CollaFix™ and OrthoFlo. AmnioFix and EpiFix are our tissue technologies processed from human amniotic membrane derived from donated placentas. Through our donor program, a mother delivering via scheduled full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 500,000 allografts to date for application in the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. The Company has recently introduced OrthoFlo, an amniotic fluid derived allograft for homologous use. Amniotic fluid is donated by consenting mothers delivering healthy babies by scheduled full-term Caesarean section births. CollaFix™, our next technology platform we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.  CollaFix™ is the only biological, biodegradable, biomimetic technology that matches human tendon in strength and stiffness.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, that the Company is continually creating new intellectual property and that it augments the Company's robust portfolio of existing patents, that the Company's aggressive approach to new patent filings and applications and enforcing its rights when its patents are infringed upon are the essential elements of protecting its intellectual property. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the patents that have been developed and the Company's approach to filing and enforcement of its rights may not provide sufficient protection of the Company's intellectual property assets, that the Company's development of patentable technology may not continue at the same pace, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2014 and its most recent Form 10Q filing. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.
Published at PR Newswire

No comments:

Post a Comment